ArticleCell death & disease2022
N6-methyladenosine demethylase FTO promotes growth and metastasis of gastric cancer via m
Article in Cell death & disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 77 citations in OpenAlex.
- The role, regulatory mechanisms, and therapeutic implications of FTO in gastrointestinal cancer.Genes & diseases · 2026Review
- New Functions of Mitochondrial Dysfunction in Gastric Cancer: From Molecular Processes to Potential Treatments.International journal of molecular sciences · 2026Review
- The Role of NMedComm · 2026Review
- RNA mCell biology and toxicology · 2026Review
- Critical roles of m6A demethylase FTO in ovarian aging.Biogerontology · 2026Review
- RNA Methylation in Cancer Metabolism: from Mechanisms to Therapeutic Opportunities.International journal of biological sciences · 2026Review
- Advances in epigenetics of gastric cancer.Oncology reviews · 2026Review
- The interplay of the microbiome, host genetics, and epigenetic modifications in gastric cancer.Frontiers in microbiology · 2026Review
- Integrative single-cell, spatial, and bulk transcriptomics reveal an FMR1-FTO axis linked to the immune-excluded phenotype in gastric cancer.Frontiers in immunology · 2026Article
- [Knockdown ofNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Mitochondria at the intersections of RNA modifications and metabolism reprogramming implications in cell death, tumor microenvironment, and immunotherapy.Journal of hematology & oncology · 2025Review
- M6a demethylase FTO regulates the oxidative stress, mitochondrial biogenesis of cardiomyocytes and PGC-1a stability in myocardial ischemia-reperfusion injury.Redox report : communications in free radical research · 2025Article
- Emerging roles of Midnolin in Cancer, Parkinson's Disease, and Metabolic dysfunction.Molecular biology reports · 2025Review
- FTO-Mediated m6A Demethylation of CCL2 Promotes Gastric Cancer Progression via Autophagy and Oxidative Stress Regulation.Digestive diseases and sciences · 2025Article
- Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.Signal transduction and targeted therapy · 2025Review
- Chemically modified non-coding RNAs in cancer.Expert reviews in molecular medicine · 2025Review
- Pescadillo ribosomal biogenesis factor 1 and programmed death-ligand 1 in gastric and head and neck squamous cell carcinoma.World journal of gastroenterology · 2025Article
- Helicobacter pylori CagA elevates FTO to induce gastric cancer progression via a "hit-and-run" paradigm.Cancer communications (London, England) · 2025Article
- The Role of N6-Methyladenosine in Mitochondrial Dysfunction and Pathology.International journal of molecular sciences · 2025Review
- The role of mitochondrial biogenesis, mitochondrial dynamics and mitophagy in gastrointestinal tumors.Cancer cell international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Gastric cancer (GC) is the fifth most common tumor and the third most deadly cancer worldwide. N6-methyladenosine (m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.